Drug Type Small molecule drug |
Synonyms TQ B3525, TQ-B3525, TQB3525 |
Target |
Mechanism PI3Kα inhibitors(Phosphatidylinositol 3 kinase alpha inhibitors), PI3Kδ inhibitors(Phosphatidylinositol 3 kinase delta inhibitors) |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Inactive Organization |
Drug Highest PhaseNDA/BLA |
First Approval Date- |
RegulationPriority Review (CN), Breakthrough Therapy (CN), Special Review Project (CN) |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Recurrent Follicular Lymphoma | NDA/BLA | CN | 22 May 2023 | |
Refractory Follicular Lymphoma | NDA/BLA | CN | 22 May 2023 | |
Advanced Lung Non-Small Cell Carcinoma | Phase 2 | CN | 11 Mar 2022 | |
Recurrent Chronic Lymphoid Leukemia | Phase 2 | CN | 05 Jun 2021 | |
Small Lymphocytic Lymphoma | Phase 2 | CN | 05 Jun 2021 | |
Endometrial Carcinoma | Phase 2 | CN | 23 Apr 2021 | |
Ovarian Cancer | Phase 2 | CN | 23 Apr 2021 | |
Uterine Cervical Cancer | Phase 2 | CN | 23 Apr 2021 | |
Diffuse Large B-Cell Lymphoma | Phase 2 | CN | 20 Jan 2021 | |
Peripheral T-Cell Lymphoma | Phase 2 | CN | 01 Dec 2020 |
Phase 2 | - | hfwmcpvayw(ukcutrkunh) = wpvatabuhv hdsuhndvny (hnrfjqzbab ) | Positive | 24 May 2024 | |||
NCT04324879 (Pubmed) Manual | Phase 2 | - | xcueqtbket(lkfurpcvfc) = kisyvdurhl hwfbphopuz (hdebyvslec ) View more | Positive | 17 Apr 2024 | ||
Phase 1 | 40 | xksjiuqlly(boxpaxymek) = jjshkycqza mrwmqoqtvd (zzucwssyod ) View more | Positive | 25 May 2020 |